Catalyst Pharmaceuticals, Inc. (CPRX) — Stock Score Summary

Catalyst Pharmaceuticals, Inc. (CPRX) has a MoatMap StockRank of 100/100 based on Quality (87/100), Value (45/100), and Momentum (78/100) factor scores. The current signal is STRONG BUY. Catalyst Pharmaceuticals, a US healthcare company, lacks a clear asymmetric opportunity driven by the identified macro themes. While healthcare is generally defensive, there isn't a specific, unpriced macro tailwind creating an inflection point for this particular business, making it a 'fine' but not a 'high-conviction' stock for this fund.

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its primary product Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS). The company holds market exclusivity for its approved rare disease therapy, addressing a significant unmet medical need for a small patient population. It is a niche biopharmaceutical company specializing in treatments for rare neurological disorders.

Key Financial Metrics

Price$31.33
Market Cap$3.8B
P/E (TTM)18.11
P/E (Forward)9.99
Price/Book3.78
Return on Equity24.5%
Return on Invested Capital26.9%
Debt/Equity0.27
Gross Margin84.0%
Operating Margin49.0%
Revenue Growth5.6%
Free Cash Flow$172M

Catalyst Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Catalyst Pharmaceuticals, Inc.’s (CPRX) StockRank?
MoatMap’s StockRank for Catalyst Pharmaceuticals, Inc. (CPRX) is 100/100, with a Strong Buy signal. It is a composite of Quality (87), Value (45), and Momentum (78) factor ranks across MoatMap’s 19,000+ stock universe.
Does Catalyst Pharmaceuticals, Inc. have an economic moat?
Catalyst Pharmaceuticals, Inc. (CPRX) has a Quality factor score of 87/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Catalyst Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Catalyst Pharmaceuticals, Inc. (CPRX) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Catalyst Pharmaceuticals, Inc. in?
Catalyst Pharmaceuticals, Inc. (CPRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCPRX deep dive reportAI ChampionsHow we score stocksSense-check another stock